protein

Human p16-INK4a

MBS695976

0.005 mg

125 USD

Recombinant Protein

Human p16-INK4a

[p16-INK4a]

[Cyclin-dependent kinase inhibitor 2A, Cyclin-dependent kinase 4 inhibitor A, CDK41, p161NK4A, p16-INK4, Multiple tumor suppressor 1, MTS-1]

[Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3; Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3; cyclin-dependent kinase inhibitor 2A; CDKN2A; CDK4 inhibitor p16-INK4; multiple tumor suppressor 1; cell cycle negative regulator beta; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A; Cyclin-dependent kinase 4 inhibitor A; CDK4I; Multiple tumor suppressor 1; MTS-1; p16-INK4a; p16-INK4; p16INK4A]

[p16-INK4a]

[CDKN2A; CDKN2A; ARF; MLM; P14; P16; P19; CMM2; INK4; MTS1; TP16; CDK4I; CDKN2; INK4A; MTS-1; P14ARF; P19ARF; P16INK4; P16INK4A; P16-INK4A; CDKN2; MTS1; CDK4I; MTS-1; p16-INK4; p16INK4A]

CD2A1_HUMAN

E Coli

Human

MEPAAGSSM EPSADWLAT AAARGRVEE VRALLEAGA LPNAPNSYG RRPIQVMMM GSARVAELL LLHGAEPNC ADPATLTRP VHDAAREGF LDTLVVLHR AGARLDVRD AWGRLPVDL AEELGHRDV ARYLRAAAG GTRGSNHAR IDAAEGPSD IPD

>= 95% by SDS-PAGE gel and HPLC analyses.

Sterile filtered through a 0.2 micron filter. Lyophilized from 1 x PBS + 1.0mM DTT, pH 7.2.

Store at -20°C

Testing Data

Authenticity: Verified by N-terminal and Mass Spectrometry analyses (when applicable). Endotoxin: Endotoxin level is <0.1 ng/ug of protein (<1 EU/ug). Protein Content: Verified by UV Spectroscopy and/or SDS-PAGE gel.

Reconstitution: Centrifuge the vial prior to opening. Reconstitute in 1x PBS, pH 8.0 to a concentration of 0.1-1.0 mg/ml. Do not vortex. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1 % BSA) and store in working aliquots at -20°C to -80°C.

Stem Cell Research; Cancer

p16-INK4a is a nuclear protein that regulates the cell cycle by inhibiting cyclin dependent kinase-4 (CDK4) and CDK6. p16-INK4a inhibits CDK activity by binding to the CDK molecules in a manner that interferes with their ability to interact with cyclin D. This activity has the effect of suppressing tumor formation and growth, and of inducing replicative senescence in various normal cells, including stem cells. The expression of p16-INK4a steadily increases with age and tends to accumulate in stem cell compartments. The deletion, rearrangement, or mutation of the p16-INK4a gene is frequently found in melanomas as well as in certain other types of cancer. Recombinant p16-INK4a is a 16.5 kDa protein containing 156 amino acid residues.

3041660

P42771.2

P42771

Apoptosis Pathway (198797); Apoptosis Modulation And Signaling Pathway (198822); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Cell Cycle Pathway (530733); Cell Cycle, Mitotic Pathway (105765); Cell Cycle Pathway (198811); Cell Cycle Pathway (83054); Cell Cycle Pathway (463); Cellular Senescence Pathway (905991)

This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]

p16-INK4A: a cell-cycle regulatory protein that interacts with CDK4 and CDK6, inhibiting their ability to interact with cyclins D. Inhibits the phosphorylation of the retinoblastoma protein by CDK4 or CDK6, and entry into the S phase of the cell cycle. The p16INK4A and p14ARF proteins are encoded by CDKN2A, a known tumour suppressor gene in multiple cancers. CDKN2A is inactivated in 72% of cases of lung squamous cell carcinoma: 21% by epigenetic silencing by methylation, 18% inactivating mutation, 4% by exon 1b skipping, and 29% by homozygous deletion. Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome, Li-Fraumeni syndrome, and the melanoma-astrocytoma syndrome. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Four alternatively spliced p16 isoforms have been reported. Two alternatively spliced isoforms of ARF have been reported. Protein type: Tumor suppressor; Cell cycle regulation; Nucleolus. Chromosomal Location of Human Ortholog: 9p21. Cellular Component: nucleoplasm; nuclear body; protein complex; mitochondrion; cytoplasm; nucleolus; cytosol; nucleus. Molecular Function: cyclin-dependent protein kinase inhibitor activity; NF-kappaB binding; protein binding; DNA binding; p53 binding; ubiquitin-protein ligase inhibitor activity; protein kinase binding; transcription factor binding. Biological Process: protein polyubiquitination; positive regulation of apoptosis; positive regulation of transcription, DNA-dependent; regulation of protein stability; negative regulation of B cell proliferation; regulation of protein export from nucleus; negative regulation of cell proliferation; apoptotic mitochondrial changes; regulation of G2/M transition of mitotic cell cycle; somatic stem cell division; cell cycle arrest; caspase activation; negative regulation of immature T cell proliferation in the thymus; transcription, DNA-dependent; protein destabilization; protein stabilization; negative regulation of cyclin-dependent protein kinase activity; negative regulation of cell-matrix adhesion; positive regulation of protein sumoylation; inhibition of NF-kappaB transcription factor; Ras protein signal transduction; negative regulation of ubiquitin-protein ligase activity; negative regulation of phosphorylation; negative regulation of protein kinase activity; positive regulation of transcription from RNA polymerase II promoter; negative regulation of cell growth; positive regulation of DNA damage response, signal transduction by p53 class mediator; mitotic cell cycle; negative regulation of transcription, DNA-dependent; rRNA processing; G1/S transition of mitotic cell cycle. Disease: Melanoma-astrocytoma Syndrome; Melanoma, Cutaneous Malignant, Susceptibility To, 2; Melanoma-pancreatic Cancer Syndrome

0.005 mg

125 USD

0.02 mg

195

0.1 mg

640

0.5 mg

1820

1 mg

2980